Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 2, 2014, Pages 446-456

  Galesloot, Tessel E ^a   Holewijn, Suzanne ^b   Kiemeney, Lambertus A L M ^a,c   De Graaf, Jacqueline ^b   Vermeulen, Sita H ^a   Swinkels, Dorine W ^d  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b Division of Vascular Medicine   (Netherlands)

^c Laboratory of Genetic Endocrine and Metabolic Diseases   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

atherosclerosis; cardiovascular disease; hepcidin; iron

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEPCIDIN; IRON;

AGE FACTORS; AGED; ANKLE BRACHIAL INDEX; BIOLOGICAL MARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; FERRITINS; HEALTH SURVEYS; HEPCIDINS; HUMANS; IRON; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; ODDS RATIO; PLAQUE, ATHEROSCLEROTIC; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; SEX FACTORS; TRANSFERRIN;

EID: 84894920502     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302381     Document Type: Article

References (45)

1. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981;1:1293-1294
2. Tuomainen TP, Loft S, Nyyssönen K, Punnonen K, Salonen JT, Poulsen HE. Body iron is a contributor to oxidative damage of DNA. Free Radic Res. 2007;41:324-328
3. Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism. 2005;54:453-459
4. Lapenna D, Pierdomenico SD, Ciofani G, Ucchino S, Neri M, Giamberardino MA, Cuccurullo F. Association of body iron stores with low molecular weight iron and oxidant damage of human atherosclerotic plaques. Free Radic Biol Med. 2007;42:492-498
5. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study. Circulation. 1997;96:3300-3307
6. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssönen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998;148:445-451
7. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002;42:1135-1139
8. Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. Heart. 1997;78:188-193
9. Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation. 2001;103:52-57
10. Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005;25:1577-1583
11. Engberink MF, Geleijnse JM, Durga J, Swinkels DW, de Kort WL, Schouten EG, Verhoef P. Blood donation, body iron status and carotid intima-media thickness. Atherosclerosis. 2008;196:856-862
12. Peffer K, den Heijer M, Holewijn S, de Graaf J, Swinkels DW, Verbeek AL, Atsma F. The effect of frequent whole blood donation on ferritin, hepcidin, and subclinical atherosclerosis. Transfusion. 2013;53:1468-1474
13. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433
14. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: Diagnostic implications. Clin Chem. 2011;57:1650-1669
15. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434-1443
16. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366:348-359
17. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: Regulation of Mammalian iron metabolism. Cell. 2010;142:24-38
18. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med (Maywood). 2007;232:1014-1020
19. Sullivan JL. Iron in arterial plaque: Modifiable risk factor for atherosclerosis. Biochim Biophys Acta. 2009;1790:718-723
20. Kuragano T, Itoh K, Shimonaka Y, Kida A, Furuta M, Kitamura R, Yahiro M, Nanami M, Otaki Y, Hasuike Y, Nonoguchi H, Nakanishi T. Hepcidin as well as TNF-α are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant. 2011;26:2663-2667
21. Van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nube MJ, Penne EL, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2012;0:1-8
22. Li JJ, Meng X, Si HP, Zhang C, Lv HX, Zhao YX, Yang JM, Dong M, Zhang K, Liu SX, Zhao XQ, Gao F, Liu XL, Cui TX, Zhang Y. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012;32:1158-1166
23. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:299-307
24. Finn AV, Nakano M, Polavarapu R, Karmali V, Saeed O, Zhao X, Yazdani S, Otsuka F, Davis T, Habib A, Narula J, Kolodgie FD, Virmani R. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59:166-177
25. Rundek T, Brook RD, Spence JD. Letter by Rundek et al regarding article, "Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-Analysis". Circulation. 2007;116:e317; author reply e318
26. Valenti L, Dongiovanni P, Motta BM, Swinkels DW, Bonara P, Rametta R, Burdick L, Frugoni C, Fracanzani AL, Fargion S. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol. 2011;31:683-690
27. Kroot JJ, van Dijk BAC, Laarakkers CMM, Janssen MCH, Kartikasari AE, Klaver SM, den Heijer M, Swinkels DW. Serum hepcidin levels are elevated in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2011;31:683-690
28. Valenti L, Swinkels DW, Burdick L, Dongiovanni P, Tjalsma H, Motta BM, Bertelli C, Fatta E, Bignamini D, Rametta R, Fargion S, Fracanzani AL. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21:568-575
29. Martinelli N, Traglia M, Campostrini N, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: A population study. PLoS One. 2012;7:e48250
30. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O, Strasser M, Datz C, Weiss G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr. 2008;87:1374-1383
31. Swinkels DW, Drenth JP. Hepcidin in the management of patients with mild non-hemochromatotic iron overload: Fact or fiction? J Hepatol. 2008;49:680-685
32. Bekri S, Gual P, Anty R, et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology. 2006;131:788-796
33. Sullivan JL. Do hemochromatosis mutations protect against iron-mediated atherogenesis? Circ Cardiovasc Genet. 2009;2:652-657
34. Galesloot TE, Geurts-Moespot AJ, den Heijer M, Sweep FC, Fleming RE, Kiemeney LA, Vermeulen SH, Swinkels DW. Associations of common variants in HFE and TMPRSS6 with iron parameters are independent of serum hepcidin in a general population: A replication study. J Med Genet. 2013;50:593-598
35. Traglia M, Girelli D, Biino G, Campostrini N, Corbella M, Sala C, Masciullo C, Viganò F, Buetti I, Pistis G, Cocca M, Camaschella C, Toniolo D. Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. J Med Genet. 2011;48:629-634
36. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713
37. Shalev H, Kapelushnik J, Moser A, Knobler H, Tamary H. Hypocholesterolemia in chronic anemias with increased erythropoietic activity. Am J Hematol. 2007;82:199-202
38. Crowley JP, Sheth S, Capone RJ, Schilling RF. A paucity of thalassemia trait in Italian men with myocardial infarction. Acta Haematol. 1987;78:249-251
39. Nemeth E. Hepcidin in beta-thalassemia. Ann N Y Acad Sci. 2010;1202:31-35
40. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92:583-588
41. Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: Implications of gender. Cardiovasc Res. 2002;53:538-549
42. Kroot JJ, Hendriks JC, Laarakkers CM, Klaver SM, Kemna EH, Tjalsma H, Swinkels DW. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: Implications for clinical studies. Anal Biochem. 2009;389:124-129
43. Schaap CC, Hendriks JC, Kortman GA, Klaver SM, Kroot JJ, Laarakkers CM, Wiegerinck ET, Tjalsma H, Janssen MC, Swinkels DW. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin Chem. 2013;59:527-535
44. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-Analysis. Circulation. 2007;115:459-467
45. Fowkes FG, Murray GD, Butcher I, et al Ankle Brachial Index Consortium. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: A meta-Analysis. JAMA. 2008;300:197-208